COMPANY

INIMMUNE CORPoration

HQ: Missoula, MT source · inimmune.com ↗ · Mountain

Keywords: food allergy oncology inflammatory diseases cancer respiratory Allergic Rhinitis influenza Allergic Rhinitis Due to Allergens Rhinitis Allergic Allergic Rhinitis Due to Weed Pollen INI-2004 INI-4001

Location: Missoula, MT · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)11NIH grants

Timeline

Jan 19, 2026 Trial start Phase 2: Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis source ↗
Jul 1, 2024 Trial start Phase 1: Trial of INI-4001 in Patients With Advanced Solid Tumours source ↗
Jul 4, 2023 Trial start Phase 1: Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis. source ↗

Upcoming milestones

Oct 30, 2026 (ESTIMATED) · Phase 1 · Trial of INI-4001 in Patients With Advanced Solid Tumours · NCT06302426

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07556393	Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis	Phase 2	Completed	Jan 19, 2026	Apr 23, 2026 (actual)
NCT06302426	Trial of INI-4001 in Patients With Advanced Solid Tumours	Phase 1	Recruiting	Jul 1, 2024	Oct 30, 2026 (estimated)
NCT06038279	Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.	Phase 1	Completed	Jul 4, 2023	Sep 5, 2024 (actual)

NIH awards 11

Annual award amounts. Total $12.2M.

2025 NIH contract (government contract; not a grant and not an investment round) 75N93023C00042-P00004-9999-1 FY2025: $1,648,211 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BURKHART, DAVID; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. DE source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93023C00042-P00001-9999-1 FY2024: $2,515,245 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BURKHART, DAVID; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. DE source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00042-0-9999-1 FY2023: $1,744,408 awarded for that fiscal year; activity N01 (OTHER_NIH); PI BURKHART, DAVID; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. DEVELOP source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00044-0-9999-1 FY2021: $1,836,453 awarded for that fiscal year; activity N44 (OTHER_NIH); PI KHALAF, JUHIENAH; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Develo source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00054-0-9999-1 FY2021: $598,808 awarded for that fiscal year; activity N01 (OTHER_NIH); PI RASHEED, OMER; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Discovery o source ↗
Aug 6, 2020 NIH award 5R44AI136081-03 FY2020: $580,244 awarded for that fiscal year; activity R44 (SBIR); PI KHALAF, JUHIENAH; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Novel synthetic TLR4 agonists source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N93020C00021-0-9999-1 FY2020: $1,992,471 awarded for that fiscal year; activity N44 (OTHER_NIH); PI MILLER, SHANNON; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Produc source ↗
Aug 30, 2019 NIH award 2R44AI136081-02 FY2019: $437,073 awarded for that fiscal year; activity R44 (SBIR); PI KHALAF, JUHIENAH; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Novel synthetic TLR4 agonists source ↗
2019 NIH contract (government contract; not a grant and not an investment round) 272201800036C-P00001-9999-1 FY2019: $41,693 awarded for that fiscal year; activity N43 (OTHER_NIH); PI KHALAF, JUHIENAH; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Disco source ↗
Feb 8, 2018 NIH award 1R43AI136081-01A1 FY2018: $176,807 awarded for that fiscal year; activity R43 (SBIR); PI KHALAF, JUHIENAH; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Novel synthetic TLR4 agonists source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201800036C-0-0-1 FY2018: $592,624 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: INIMMUNE CORPORATION, MISSOULA, MT. Discovery of new small mo source ↗